

**Date:** 27<sup>th</sup> April 2015

**Minutes:** Final

**Guideline Development Group Meeting 4 Parkinson's Disease**

**Place:** NICE Offices, Level 1a, City Tower, Piccadilly Plaza, Manchester, M1 4BT

**Present:** Paul Cooper (Chair)  
Alistair Church (AC)  
Fiona Lindop (FL)  
Graham Lennox (GL)  
Ivan Benett (IB)  
Jane Little (JL)  
Janine Barnes (JB)  
Matthew Sullivan (MS)  
Richard Grunewald (RG)  
Debbie Davies (DD)  
Paul Shotbolt (PS)  
Richard Walker (RW)  
Nicholas Miller (NM) – co-opted expert

**Apologies:** Lynne Osborne (LO)  
Robin Fackrell (RF)

**In attendance:**

**NICE Staff:**

Laura Downey (LD)  
Stephanie Mills (SM)  
Steven Ward (SWard)  
Gabriel Rogers (GR)  
Sarah Stephenson (SS)  
Sarah Palombella (SP)  
Jenny Kendrick (JK)

**Observers:**

Johanna Hulme – (present from 3pm)	NICE Medicines Prescribing Centre	
Louise Bates – (present from 3pm)	NICE Medicines Prescribing Centre	

**Monday 27<sup>th</sup> April 2015**

1. PC welcomed the group to the fourth meeting of this guideline committee. Apologies

were received from LO and RF. No further conflicts of interest above what had been made known to the NICE team were declared by any other person present.

The committee looked over the minutes of the previous meeting and agreed they were an accurate representation of the meeting in February 2015.

PC explained that the meeting would include looking at some of the evidence on speech and language therapy, the information needs of women of childbearing age with Parkinson's disease and agreeing further review protocols.

2. SP presented to the group on the role of the editor in development of the guideline. The different NICE products which contain the guideline recommendations and support dissemination of the guidance were explained to the group. The editor went through the different ways NICE wording reflects the strength of the evidence base and also stated that recommendations are written as active statements which direct healthcare professionals as to the action they should take. The committee were encouraged to ensure their ideas were captured accurately in meetings but not to worry about the exact word crafting as this would be checked with the editor.
3. LD presented the evidence review on speech and language therapy. There was little new evidence from the previous iteration of this question in clinical guideline 35. NM explained what an attention to effort treatment programme would ordinarily include and the impact of Parkinson's disease on the ability to communicate and swallow. MS and JL also gave their perspectives on this and how speech and language therapy can be beneficial on communication but also overall quality of life. The committee considered the recommendations from the previous guideline and how clinical expertise and the evidence would impact on what already existed.
4. SWard talked with the committee about health economics. There was discussion about the different health states which would need to be within the model and how these could be adapted to reflect clinical reality. There was also some discussion about what data could be useful to the model and which options for treatment of advanced stage Parkinson's disease would be suitable for different people.
5. LD presented a second evidence review on the information needs of women with Parkinson's disease of childbearing age. There was very limited low quality evidence for the committee to consider. There was discussion around the presented evidence, anecdotal evidence from clinical practical and the ethical issues of making bold statements in this area. The committee came to a consensus on recommendations.
6. The committee signed off review protocols for a number of upcoming reviews. There was lengthy discussion about the review questions looking at pharmacological management of Parkinson's disease and motor symptoms. There was a query from the committee about whether an additional question around sleep disorders could be considered. The NICE team said that they would take this back for consideration.

### **Date, time and venue of the next meeting**

Next meeting – 8<sup>th</sup> June 2015, Avonmouth House, London from 10:30am – 5pm.

- **Review question 7:** *What is the effectiveness of occupational therapy (OT) compared with usual care on the following complications of PD?*
- **Review question 8:** *What factors should healthcare professionals consider as potential predictors for the development of impulse control behaviours as an adverse effect of*

*dopaminergic treatment?*

- ***Ratify review protocols***